CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA Article

Odia, Yazmin, Wen, Patrick, Mehta, Minesh et al. (2021). CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA . NEURO-ONCOLOGY, 23(Supplement_6), vi62-vi63. 10.1093/neuonc/noab196.242

cited authors

  • Odia, Yazmin; Wen, Patrick; Mehta, Minesh; Colman, Howard; Dunbar, Erin; Butowski, Nicholas; Harrison, Rebecca; Schulder, Michael; Boockvar, John; Chow, Frances; Kumthekar, Priya; Mason, Warren; Venur, Vyshak; Plotkin, Scott; Lassman, Andrew; Duic, Paul; Tamir, Sharon; Li, Kai; Liu, Yang; Mundy, Gregory; Damestani, Yasaman; Sbar, Eric; Shah, Jatin; Shacham, Sharon; Goldlust, Samuel

authors

publication date

  • November 12, 2021

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • 6.2 Cellular and gene therapies
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi62

end page

  • vi63

volume

  • 23

issue

  • Supplement_6